Table 1.

Baseline demographical, clinical, and biochemical parameters of the total study population and the two subgroups: Calcium acetate-treated patients and sevelamer hydrochloride-treated patientsa

ParameterAllCalcium AcetateSevelamer HydrochlorideReference Values
n401921
Age (yr)50.38 ± 11.4051.21 ± 9.9849.62 ± 12.75
Body mass index (kg/m2)26.28 ± 4.5826.95 ± 4.1625.67 ± 4.9518 to 25
Gender (male/female)21/199/1012/9
Cr (mg/dl; male/female)2.55 ± 0.782.52 ± 0.762.59 ± 0.820.8 to 1.2/0.6 to 1.0
CrCl (ml/min/1.73 m2; male/female)34.55 ± 15.8932.07 ± 9.9236.9 ± 2085 to 125/75 to 115
Bic (mmol/L)21.63 ± 3.7920.82 ± 2.9722.37 ± 4.3423 to 30
Alb (g/dl)4.35 ± 0.304.35 ± 0.214.36 ± 0.373.5 to 5
Ca (mg/dl)9.29 ± 0.509.34 ± 0.569.24 ± 0.458.6 to 10.2
P (mg/dl)3.53 ± 0.603.61 ± 0.543.45 ± 0.652.7 to 4.5
TAP (U/L)81.20 ± 21.7284.42 ± 25.3278.29 ± 18.0135 to 104
BAP (U/L)35.10 ± 11.4636.91 ± 12.6233.46 ± 10.3511.6 to 42.7
DPD (nmol/L)10.32 ± 3.389.81 ± 3.2510.80 ± 3.523.25 ± 0.66
25vitD (ng/ml)34.75 ± 20.6535.71 ± 18.6633.88 ± 22.73> 30
1,25vitD (pg/ml)31.27 ± 21.1832.82 ± 16.6729.79 ± 25.0815.9 to 55.6
PTH (pg/ml)101 (70 to 130) 89 (52 to 141)107 (76 to 130) 10 to 65
FGF23 (pg/ml)97 (64 to 142)97 (62 to 148)103 (62 to 142) 8.2 to 54.3
uCa (mg/24 h)24.27 ± 25.6123.39 ± 24.4925.11 ± 27.27100 to 320
uP (mg/24 h)490.5 ± 150.9444.5 ± 154.6534.1 ± 137.3400 to 1300
FeP (%)59.7 ± 32.458.2 ± 37.261.0 ± 28.45 to 18
uProt (g/24 h)0.45 ± 0.750.35 ± 0.670.55 ± 0.82<0.1
  • a Mean ± SD values are shown [except for PTH and FGF23, which are expressed as median (25th to 75th percentile interval)]. Cr, creatinine; CrCl, creatinine clearance; Ca, serum calcium; P, serum phosphate; Bic, serum bicarbonate; Alb, serum albumin; TAP, total alkaline phosphatase; BAP, bone alkaline phosphatase; DPD, deoxypyridinoline; 25vitD, 25-vitamin D; 1,25vitD, 1,25-vitamin D; uCa, urinary calcium; uP, urinary phosphate; FeP, fractional excretion of phosphate; uprot, urinary protein.